Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America

Liver International

Volumn 36, Issue 11, 2016, Pages 1657-1667

  Piñero, Federico ^a   Tisi Baña, Matías ^a   de Ataide, Elaine Cristina ^b   Hoyos Duque, Sergio ^c,d   Marciano, Sebastian ^e   Varón, Adriana ^f   Anders, Margarita ^g   Zerega, Alina ^h   Menéndez, Josemaría ⁱ   Zapata, Rodrigo ^j,k   Muñoz, Linda ^l   Padilla Machaca, Martín ^m   Soza, Alejandro ⁿ   McCormack, Lucas ^g   Poniachik, Jaime ^o   Podestá, Luis G ^a   Gadano, Adrian ^e   Boin, Ilka S F Fatima ^b   Duvoux, Christophe ^p   Silva, Marcelo ^a   Andriani, Oscar ^q   Gil, Octavio ^q   Barrabino, Martín ^q   Maraschio, Martín ^q   Boteon, Yuri Longatto ^q   Diaz, Juan Carlos ^q   Montenegro, Cristian ^q   Ibarra, Jose ^q   Jarufe, Nicolas ^q   Restrepo, Juan Carlos ^q   Hoyos, Isabel Arenas ^q   Santos, Luisa ^q   Garzón, Martín ^q   Rondon, Carlos ^q   Chaman, Jose ^q   Gerona, Solange ^q   more..

^a UNIVERSIDAD AUSTRAL   (Argentina)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c HOSPITAL PABLO TOBÓN URIBE   (Colombia)

^d UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^e HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^f FUNDACIÓN CARDIOINFANTIL INSTITUTO DE CARDIOLOGÍA   (Colombia)

^g HOSPITAL ALEMÁN   (Argentina)

^h Sanatorio Allende   (Argentina)

ⁱ Hospital Militar   (Uruguay)

^j UNIVERSIDAD DEL DESARROLLO   (Chile)

^k UNIVERSITY OF CHILE   (Chile)

^l HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^m HOSPITAL NACIONAL GUILLERMO ALMENARA IRIGOYEN   (Peru)

ⁿ PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^o HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^p HENRI MONDOR HOSPITAL   (France)

^q NONE

more..

Author keywords

alpha fetoprotein; candidate selection; liver cancer; prediction

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CHRONIC HEPATITIS B; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE; PREDICTIVE VALUE; RECURRENCE RISK; SOUTH AND CENTRAL AMERICA; SURVIVAL RATE; TUMOR RECURRENCE; AGED; BLOOD; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; DIAGNOSIS; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS;

AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LATIN AMERICA; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84976873467     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13159     Document Type: Article

References (29)

1. Mazzaferro VV, Regalia EE, Doci RR, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–9.
2. Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011; 17: S44–57.
3. Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 2004; 127: S261–7.
4. Davis E, Wiesner R, Valdecasas J, et al. Treatment of recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2011; 17: S162–6.
5. Toso C, Mentha G, Majno P. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant 2011; 11: 2031–5.
6. Shin WY, Suh K-S, Lee HW, et al. Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2010; 16: 678–84.
7. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394–403.
8. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35–43.
9. Toso C, Trotter J, Wei A, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008; 14: 1107–15.
10. Vibert E, Azoulay D, Hoti E, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2009; 10: 129–37.
11. Ravaioli M, Grazi GL, Piscaglia F, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008; 8: 2547–57.
12. Yao FY, Kerlan RK Jr, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48: 819–27.
13. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level >1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl 2014; 20: 945–51.
14. Duvoux C, Thoraval FR, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986–994.e3.
15. Notarpaolo A, Bizouard G, Gambato M, et al. Prediction of recurrence after liver transplantation for HCC: validation of the AFP model in an Italian cohort. Liver Transplant 2014; 20: S133.
16. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208–36.
17. Villanueva A, Hoshida Y, Battiston C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011; 140: 1501–1512.e2.
18. Majno P, Lencioni R, Mornex F, et al. Is the treatment of hepatocellular carcinoma on the waiting list necessary? Liver Transpl 2011; 17: S98–108.
19. Welker M-W, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular carcinoma after liver transplantation – an emerging clinical challenge. Transplant Int 2012; 26: 109–18.
20. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453–7.
21. Sharma P, Schaubel DE, Sima CS, Merion RM, Lok ASF. Re-weighting the model for end-stage liver disease score components. Gastroenterology 2008; 135: 1575–81.
22. Toso C, Asthana S, Bigam DL, Shapiro AMJ, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database. Hepatology 2008; 49: 832–8.
23. Yao FY, Hirose R, LaBerge JM, et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005; 11: 1505–14.
24. Wong LL, Naugler WE, Schwartz J, et al. Impact of locoregional therapy and alpha-fetoprotein on outcomes in transplantation for liver cancer: a UNOS Region 6 pooled analysis. Clin Transplant 2012; 27: E72–9.
25. Cescon M, Ravaioli M, Grazi GL, et al. Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma. J Transplant 2010; 2010: 1–8.
26. Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl 2013; 19: 634–45.
27. Otto G, Schuchmann M, Hoppe-Lotichius M, et al. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? J Hepatol 2013; 59: 279–84.
28. Dumitra TC, Dumitra S, Metrakos PP, et al. Pretransplantation α-fetoprotein slope and Milan criteria. Transplantation 2013; 95: 228–33.
29. European Association for the Study of the Liver. European Organization for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908–43.